Is the price fair?
What NVS's price assumes
Novartis AG trades at 23.3× earnings against 27.4× for the median Drug Manufacturers - General name, cheaper than its own group.
23.3
Trailing P/E · Drug Manufacturers - General median 27.4 · cheaper than the typical name in its group
- Price / sales
- 3.17
Price / sales · as of 2025-H2
- Free cash flow yield
- 5.8%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- +3.6%
Growth the price implies · The price pays for +3.6% free cash flow growth a year for a decade; the business has delivered +15% a year over the last three.
Details›
- Price / book2025-H2
- 5.53
- EV / EBIT2025-H2
- 11.0
- EV / sales2025-H2
- 3.39
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $16.4B
- Market capitalisation
- $280.6B
- 3-year revenue growth
- +4.5%
- 3-year free cash flow growth
- +15%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #10 of 16 by Smart Score